Back to top

Analyst Blog

Zacks Equity Research

DARA Biosciences Inks Deal

DARA

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

DARA Biosciences, Inc. (DARA) recently entered into an exclusive distribution agreement with Seyer Pharmatec Inc. to sell and distribute the breast cancer product Soltamox in the Commonwealth of Puerto Rico. The company intends to launch Soltamox later in the year.

Soltamox is the first and only oral liquid formulation for breast cancer to be approved by the US Food & Drug Administration (FDA). Soltamox is marketed in the US by DARA. License to sell Soltamox in the US was granted by Rosemont Pharmaceuticals.

We note that many patients suffering from breast cancer face problems in swallowing pills. So an oral liquid formulation will be a convenient, comfortable and easy-to-swallow alternative for women with breast cancer.

In January, this year DARA acquired South Carolina-based specialty pharmaceutical company, Oncogenerix, Inc. Oncogenerix held an exclusive license for the US marketing rights to Soltamox from Rosemont. After Oncogenerix’ acquisition DARA now enjoys the rights to market the product in the US. Rosemont markets Soltamox in the UK and Ireland.

We remind investors that in June, this year, DARA launched its first product Bionect which treats skin irritation and burns associated with radiation therapy. The company introduced the product for the cancer care market across the US.

An important oncology candidate at DARA is KRN5500 (completed phase IIa study). The company’s pipeline also includes DB959 (type 2 diabetes).

Our Recommendation

Currently, we have a Neutral long-term stance on DARA. The company carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%